NASDAQ2020
13 hours ago
Toppin off for THE LAUNCH !
ELTP Catalysts:
Next 1-day to 6 months
X 1. Cash Flow Positive - 5 years
X 2. Purchase building housing their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
X 3. Adderall IR $335 Million IMS market Approved and Launched
X 4. Adderall XR $1.56 Billion IMS market Approved and Launched
X 5. Double digit quarterly revenues in millions
X 6. Create in house marketing and distribution: Kirko Kirkov, Doug Plassche and their teams
X 7. Prasco/Burel Adderall agreement - January 1st 2024
X 8. First shipment Adderall XR to Prasco/Burel Dec 2023
X 9. DEA increases manufacturing quotas for Adderall & Vyvance
X 10. Generic OxyContin - FIRST TO FILE FDA Aug 17, 2023 $720 Million
X 11. Generic Vyvanse - $4.7 BILLION - FDA submission Dec 2023
X 12. FDA Acceptance of Generic OxyContin Sept 2023
X 13. Lease additional manufacturing space and storage vault for new Needle Mover ANDAs - Jan 2024
__14. Dopamine Agonist Approval (probably Requip XL or Mirapex ER). $12 Million
__15. Obtain Full ownership of Adderall IR $ 335 Million from MIKAH
__16. Obtain Full ownership of Adderall XR $ 1.56 Billion from MIKAH
X 17. Vigabatrin Approval $233 Million
X 18. Pyros Vigabatrin -settle VigPoder trade mark challenge and LAUNCH
X 19. Generic Methotrexate Antimetabolite- Approval
X 20. Launch generic Methotrexate $63.4 Million
X 21. $50+ million in yearly revenues
X 22. Lowest PE ratio for OTC Healthcare sector
X 23. Become the ONLY company showing rapid growth on the OTC while being profitable
X 24. Put Opioids back on the Table- due to reduced risk of opioid litigation
X 25. Receive Analyst Coverage - Upgrade to Market Outperform - Zacks Investment Research
__26. Generate revenues over $20 million/quarter
__27. Final Approval of New Manufacturing Facility/Expansion
__28. Double output of manufacturing and packaging facilities
X 29. Launch approved generic Tylenol with Codeine $47 Million
__30. Launch approved generic Norco - hydrocodone acetaminophen IMS $477 Million
__31. Launch approved generic Percocet - oxycodone acetaminophen IMS $500 Million
__32. Launch approved generic Dolophine - methadone HCL tablets IMS $30 Million
X 33. Godzilla -Generic Vyvanse Approval $4.3 Billion
__34. Positive BE Study for Concerta CNS Stimulant $1.2 Billion
__35. Godzilla - Generic Vyvance LAUNCH $4.3 Billion
__36. Generic Concerta- FDA submission $1.2 Billion
__37. $100 million in yearly revenues
__38. Generic OxyContin Tentative Approval $720 Million
__39. Elite prevail over Purdue in Generic OxyContin infringement suit - second 6 month stay - active Accord/Purdue suit causing delay
__40. Launch generic OxyContin $720 Million
__41. Positive BE on NDA Unique ADF opioid - 90% cheaper than ADF without Naltrexone - Game Over Drug
__42. Resume R&D on SequestOx Abuse Deterrent Oxycodone
X 43. International Distribution - partnership Approval by Israeli Ministry of Health for European distribution License and Distribution Agreement by and between Elite Pharmaceuticals, Inc. and Dexcel Ltd.
X 44. Generic IR Adderall® Receives Marketing Approval From The Israeli Ministry Of Health Oct 2024
__45. $200 million in yearly revenue
__46. Patented NDA Unique ADF (w/o naltrexone) drug C in SequestOx reformulation trial
__47. Undisclosed Mikah ANDA(s)
__48. Undisclosed ANDAs/NDAs
__49. Generic Concerta Launch $1.2 Billion
__50. DollarLand PPS
__51. Big Pharma bidding
__52. UpList to the NASDAQ Exchange
__53. ELTP Elite Pharmaceutical Buyout - 2 1/2 years or less from Feb 2024
__54. Vegas BABY !!!!!
kayak_wench
2 days ago
Yes, you are now set up very nicely, but you may have to wait a while for the big payoff. I doubt anything big will happen until the trial is over and the publication is out. Hopefully that is in a very highly regarded publication (like JAMA). That could be a full year away (trial wraps up by summer and then it takes a few months to write a paper and a few months for it to be published). I believe how much attention the trial gets at that point of publication will be key. That is when new medical treatments can get into the mainstream news. In the meantime, fankly, I expect to lose money on the investment I took out today. At least until trial results are in, but I hope I'm wrong. Data can be fed to FDA in the meantime so maybe a movement on trials here in the U.S, but then those would have to be paid for. Investing in OTC is a lot of waiting.
Thankfully the wait here at Elite is very close to being over. Worst case here is 6 months for a full quarter of revenue of Vyvanse to be recognized.